Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

2d ago, source:

Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious ConditionsSOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- , Inc.

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

1mon ago, source: Business Insider

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...

Artelo Biosciences highlights FABP7's role in cancer

2d ago, source: Investing

SOLANA BEACH, Calif. - Artelo Biosciences , Inc. (NASDAQ:ARTL), a clinical-stage biopharmaceutical company, announced today the publication of a research article in the peer-reviewed journal Drug ...

Artelo Biosciences Inc ARTL

22d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Artelo Biosciences Inc ARTL

10d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Artelo Biosciences Inc. Wt

29d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Artelo Biosciences, Inc. (ARTL)

10d ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Artelo Biosciences Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...